Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Safer brain scans: no contrast needed for meningioma detection?

NCT ID NCT04113408

Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether special MRI sequences (FABIR) can spot meningiomas without using gadolinium contrast dye, which can build up in the body after many injections. Researchers compared the new method to standard contrast MRI in 315 adults undergoing screening or follow-up for meningioma. The goal was to see if the dye-free approach is accurate enough to replace contrast scans, reducing long-term risks for patients who need repeated imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

315 people

The number who actually took part.

Started

Jun 2020

Finished

Jun 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting to the radiology department of the A. de Rothschild Foundation for an MRI, as part of a screening or monitoring of meningioma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years of age * Patient performing MRI as part of a screening or follow-up of known meningioma * Express consent to participate in the study Exclusion Criteria: * Contraindication for MRI (electrical device, metallic foreign body, claustrophobia) * Known hypersensitivity to the contrast medium (Gadolinium) * Known renal failure: glomerular filtration rate \<30mL/min * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

meningioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meningioma

Contacts and locations

Locations

  • Fondation ophtalmique Adolphe de Rothschild

    Paris, Paris, 75019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.